Liquidia’s (LQDA) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright restated their buy rating on shares of Liquidia (NASDAQ:LQDA) in a research report sent to investors on Monday,Benzinga reports. The brokerage currently has a $29.00 price target on the stock.

A number of other analysts also recently issued reports on the company. Raymond James lifted their price objective on Liquidia from $27.00 to $29.00 and gave the stock a “strong-buy” rating in a research note on Friday, May 9th. Scotiabank reaffirmed an “outperform” rating on shares of Liquidia in a research note on Monday, May 5th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $25.00 price objective on shares of Liquidia in a research note on Thursday, April 10th. One research analyst has rated the stock with a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $27.13.

Liquidia Price Performance

Shares of NASDAQ:LQDA opened at $18.65 on Monday. The company has a market capitalization of $1.59 billion, a P/E ratio of -11.44 and a beta of 0.24. Liquidia has a 1-year low of $8.26 and a 1-year high of $18.89. The firm’s 50 day simple moving average is $14.35 and its two-hundred day simple moving average is $13.27.

Liquidia (NASDAQ:LQDA) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.03). Liquidia had a negative net margin of 765.38% and a negative return on equity of 163.21%. The company had revenue of $3.12 million during the quarter, compared to the consensus estimate of $3.23 million. On average, sell-side analysts anticipate that Liquidia will post -1.51 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, insider Jason Adair sold 1,856 shares of the stock in a transaction on Monday, April 14th. The shares were sold at an average price of $13.57, for a total value of $25,185.92. Following the sale, the insider now owns 184,304 shares of the company’s stock, valued at approximately $2,501,005.28. This represents a 1.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Rajeev Saggar sold 2,450 shares of the firm’s stock in a transaction dated Monday, April 21st. The stock was sold at an average price of $13.67, for a total transaction of $33,491.50. Following the completion of the sale, the insider now owns 263,152 shares of the company’s stock, valued at $3,597,287.84. This trade represents a 0.92% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 33,138 shares of company stock worth $450,233 over the last three months. 30.10% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of LQDA. Hurley Capital LLC bought a new stake in shares of Liquidia during the 1st quarter worth approximately $32,000. GAMMA Investing LLC increased its stake in Liquidia by 65.6% in the first quarter. GAMMA Investing LLC now owns 2,961 shares of the company’s stock worth $44,000 after purchasing an additional 1,173 shares during the period. Steward Partners Investment Advisory LLC bought a new stake in shares of Liquidia during the fourth quarter worth $59,000. Summit Investment Advisors Inc. grew its holdings in shares of Liquidia by 35.0% in the fourth quarter. Summit Investment Advisors Inc. now owns 6,632 shares of the company’s stock worth $78,000 after purchasing an additional 1,719 shares during the last quarter. Finally, D. E. Shaw & Co. Inc. purchased a new position in Liquidia in the 4th quarter worth about $142,000. Institutional investors own 64.54% of the company’s stock.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).